About: The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States
Creator	Shen, Yao Realubit, Ronald Alvarez, Mariano Bosker, Gideon Califano, Andrea Douglass, Eugene Karan, Charles Laise, Pasquale Pampou, Sergey Sun, Xiaoyun
Source	BioRxiv; Medline; PMC
abstract	Most antiviral agents are designed to target virus-specific proteins and mechanisms rather than the host cell proteins that are critically dysregulated following virus-mediated reprogramming of the host cell transcriptional state. To overcome these limitations, we propose that elucidation and pharmacologic targeting of host cell Master Regulator proteins—whose aberrant activities govern the reprogramed state of coronavirus-infected cells—presents unique opportunities to develop novel mechanism-based therapeutic approaches to antiviral therapy, either as monotherapy or as a complement to established treatments. Specifically, we propose that a small module of host cell Master Regulator proteins (ViroCheckpoint) is hijacked by the virus to support its efficient replication and release. Conventional methodologies are not well suited to elucidate these potentially targetable proteins. By using the VIPER network-based algorithm, we successfully interrogated 12h, 24h, and 48h signatures from Calu-3 lung adenocarcinoma cells infected with SARS-CoV, to elucidate the time-dependent reprogramming of host cells and associated Master Regulator proteins. We used the NYS CLIA-certified Darwin OncoTreat algorithm, with an existing database of RNASeq profiles following cell perturbation with 133 FDA-approved and 195 late-stage experimental compounds, to identify drugs capable of virtually abrogating the virus-induced Master Regulator signature. This approach to drug prioritization and repurposing can be trivially extended to other viral pathogens, including SARS-CoV-2, as soon as the relevant infection signature becomes available.
has issue date	2020-05-17(xsd:dateTime)
bibo:doi	10.1101/2020.05.12.091256
bibo:pmid	32511361
has license	cc-by-nd
sha1sum (hex)	0394f76ecf36fbd063764e40a2b3f37ff31b1e46
schema:url	https://doi.org/10.1101/2020.05.12.091256
resource representing a document's title	The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States
has PubMed Central identifier	PMC7263489
has PubMed identifier	32511361
schema:publication	bioRxiv
resource representing a document's body	covid:0394f76ecf36fbd063764e40a2b3f37ff31b1e46#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'govern' named entity 'release' named entity 'hijacked' named entity 'Master' named entity 'host' named entity 'proteins' named entity 'host' named entity 'proteins' covid:arg/0394f76ecf36fbd063764e40a2b3f37ff31b1e46 named entity 'cell' named entity 'drug' named entity 'FDA-approved' named entity 'monotherapy' named entity 'abrogating' named entity 'interferon' named entity 'virus' named entity 'yeast' named entity 'ebola' named entity 'oncology' named entity 'virus-mediated' named entity 'Master Regulator' named entity 'mechanism-based' named entity 'SARS-CoV' named entity 'unique' named entity 'replication' named entity 'host cell' named entity 'Master Regulator' named entity 'virus-mediated' named entity 'host cell' named entity 'host cell' named entity 'host cells' named entity 'NYS' named entity 'FDA' named entity 'virus' named entity 'pharmacologic' named entity 'transcriptional' named entity 'protein synthesis' named entity 'virus' named entity 'L-glutamine' named entity 'proof-of-concept' named entity 'DMSO' named entity 'regulatory network' named entity 'trametinib' named entity 'antivirals' named entity 'FDA' named entity 'viruses' named entity 'Correlation' named entity 'statistically significant' named entity 'Small-molecule' named entity 'respiratory syncytial virus' named entity 'proteases' named entity 'macrophages' named entity 'IL-6' named entity 'CDK4' named entity 'coronaviruses' named entity 'host cell' named entity 'NCI' named entity 'SARS-CoV-2 virus' named entity 'nasal mucosa' named entity 'BUB1B' named entity 'acyclovir' named entity 'virus' named entity 'viral pathogens' named entity 'lung adenocarcinoma' named entity 'dasatinib' named entity 'fetal bovine serum' named entity 'MAP kinase' named entity 'Differential gene expression' named entity 'chikungunya' named entity 'DMEM' named entity 'TFs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software